"The chief executive of ASX-listed medtech Anteris Technologies says the company's replacement heart valve will take "at least" 50% of the US$10 billion sector when it comes to market, which could one day value the company at US$25 billion." (emphasis mine)
It's absolutely essential that everyone recognises here the words "at least."
We are in a position now (albeit with only a small population size of DurAVR patients) where the technology's competitive benefits over the TAVR's currently available have been unequivocally proven (in high risk patients!)
They have, by all parameters currently used to measure performance of TAVR's and even some which weren't previously used (laminar flow) smashed our peers.
Whereas our peers return the patient to a mild diseased state our TAVR returns the patient to a pre-diseased state.
So when Mr Paterson says "at least" 50% it is, I believe, just his attempt at modesty.
We have world leaders in TAVR saying things like DurAVR will take a "massive" share of the market and that the DurAVR is a "valve for all patients."
It is my belief, a belief backed up by historic, never seen before results, that to a rounding error the DurAVR will take the entire TAVR market.
We are onto something huge here and as each week passes more and more professionals are starting to recognize that.
AVR Price at posting:
$25.00 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)